Get involved in the discussion! Click here to comment on this story
Sanofi’s ready to say farewell to Bangladesh, local media reports, despite pleas from government officials to stay put.
After more than 60 years in the country, the drugmaker has notified the Bangladesh Chemical Industries Corporation (BCIC)—which owns about 20% of the company’s local outfit—that it’s planning to exit, the Financial Express reports.
BCIC officials are pressing Sanofi to stay, but the company’s planning to move out for strategic reasons, The Daily Star reports. It could continue supplying medicines to Bangladesh through imports, according to the reports.
As of 2016, Sanofi was the largest pharma company in Bangladesh with more than 1,200 employees there, according to a paper published in the International Journal of Business and Management. It operates a plant in Tongi, according to an SEC filing, and maintains a corporate office in Dhaka.
To make its exit, Sanofi aims to sell its approximately 55% share in the local company. The Bangladeshi government owns the remaining 45%, according to reports.
The move follows GlaxoSmithKline’s Bangladesh exit last year; that company found the market “not sustainable,” according to the Financial Express report.
For Sanofi, the reported exit also comes after the company sold its generics outfit Zentiva to Advent International for $2.2 billion last year. The generics company has a global manufacturing footprint and about 3,000 employees. Earlier this month, Advent bought a Sanofi manufacturing plant in India for $36.5 million.
If Sanofi does in fact exit Bangladesh, it may well be one of the first moves authorized by new Sanofi CEO Paul Hudson. He took up the role at the beginning of this month, replacing Olivier Brandicourt, who retired. During his four-year CEO stint, Brandicourt worked to cut costs and refocus the company around five business units.
A Sanofi representative didn’t immediately comment on the reports.
By Eric Sagonowsky
Source: Fierce Pharma
LinkedIn Twitter FacebookIndustry watchers largely expected that Bristol-Myers Squibb and Celgene would win U.S. antitrust clearance for their $74 billion merger. But what’s perhaps unexpected is that the permission was […]
LinkedIn Twitter FacebookNovartis is calling it curtains on early drug discovery at its R&D site in Shanghai in a companywide move to “rebalance” its discovery and early development efforts. The […]
LinkedIn Twitter FacebookMerck & Co has had mixed fortunes in neurological diseases of late, but remains committed to the category and has just bolstered its early-stage pipeline with a $576 […]